{"created":"2023-05-18T10:11:19.151453+00:00","id":3053,"links":{},"metadata":{"_buckets":{"deposit":"95441fc2-bcb1-45f2-9d49-2c0b36a39406"},"_deposit":{"created_by":5,"id":"3053","owners":[5],"pid":{"revision_id":0,"type":"depid","value":"3053"},"status":"published"},"_oai":{"id":"oai:yamanashi.repo.nii.ac.jp:00003053","sets":["205:251:274"]},"author_link":["14102","14103","14104","14105","14106","14107","14108"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1997","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"51","bibliographicPageStart":"45","bibliographicVolumeNumber":"12","bibliographic_titles":[{"bibliographic_title":"山梨医科大学雑誌","bibliographic_titleLang":"ja"},{"bibliographic_title":"Yamanashi medical journal","bibliographic_titleLang":"en"}]}]},"item_10001_creator_2":{"attribute_name":"著者名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Tawata, Masato","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Aida, Kaoru","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Inoue, Masaharu","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kurihara, Akihiro","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Iwase, Eiichi","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Gan, Naoya","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Onaya, Toshimasa","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_10001_description_5":{"attribute_name":"内容","attribute_value_mlt":[{"subitem_description":"We evaluated the effects of epalrestat on subjective symptoms and vibration sensation in type 2 diabetic patients with neuropathy. The patients were administered epalrestat 150 mg/day orally in three divided doses for 3 months (treatment period), and the agent was discontinued for 3 months (washout period). Epalrestat relieved numbness in 12 of 16 patients after the treatment period, and numbness worsened in 5 of 11 patients after the washout period. Chi-square analysis revealed significant effects of epalrestat on numbness (p<0.001) and also on other symptoms (p<0.05). Vibration sensation was evaluated by measuring vibratory threshold using an SMV-5 vibrometer. The vibratory threshold significantly decreased in the upper (p<0.05) and the lower (p<0.01) extremities after the treatment period and increased in the lower extremity (p<0.05) after the washout period by paired t-test. There was no significant change in glycosylated hemoglobin as a whole during the study. These observations confirm that epalrestat relieves subjective symptoms and improves vibration sensation in type 2 diabetic patients with neuropathy without affecting glycemic control.","subitem_description_language":"en","subitem_description_type":"Other"}]},"item_10001_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.34429/00003046","subitem_identifier_reg_type":"JaLC"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"山梨医科大学医学会","subitem_publisher_language":"ja"}]},"item_10001_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AN10044054","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0912-0025","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-02-27"}],"displaytype":"detail","filename":"AN10044054_12_02_02.pdf","filesize":[{"value":"673.0 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"AN10044054_12_02_02.pdf","objectType":"fulltext","url":"https://yamanashi.repo.nii.ac.jp/record/3053/files/AN10044054_12_02_02.pdf"},"version_id":"36a175b2-8a0f-4688-a5b0-3e8716fbb1b2"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Epalrestat","subitem_subject_language":"en"},{"subitem_subject":"Aldose reductase inhibitor","subitem_subject_language":"en"},{"subitem_subject":"Diabetic neuropathy","subitem_subject_language":"en"},{"subitem_subject":"Vibratory threshold","subitem_subject_language":"en"},{"subitem_subject":"SMV-5 vibrometer","subitem_subject_language":"en"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"<Original Article> The Effects of Epalrestat on Subjective Symptoms and Vibratory Threshold in Type 2 Diabetic Patients with Neuropathy","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"<Original Article> The Effects of Epalrestat on Subjective Symptoms and Vibratory Threshold in Type 2 Diabetic Patients with Neuropathy","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"5","path":["274"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2010-05-18"},"publish_date":"2010-05-18","publish_status":"0","recid":"3053","relation_version_is_last":true,"title":["<Original Article> The Effects of Epalrestat on Subjective Symptoms and Vibratory Threshold in Type 2 Diabetic Patients with Neuropathy"],"weko_creator_id":"5","weko_shared_id":-1},"updated":"2023-10-11T07:35:03.524922+00:00"}